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This timely debate tries to address a common clinical
problem faced by movement disorders specialists. Fol-
lowing the initial impressive improvement gained by
dopaminergic medications, many patients develop dyski-
nesias and ﬂuctuations which are clearly drug related. The
pathogenesis of these problems is still unclear, but the most
reasonable explanation is that with the ongoing degenera-
tion of dopaminergic pathways in the striatum, the ability
of these terminals to regulate or stabilize the synaptic
concentration of dopamine is lost. Thus a direct relation-
ship between blood levels and motor effect is reached,
leading to insufﬁcient or excessive stimulation of post-
synaptic dopamine receptors (Korczyn 1972). Attempts to
control the dopaminergic tone by frequent smaller doses
are of minor help at best.
These pharmacokinetic considerations have led to the
development of two methods which allow continuous sta-
ble serum levels of dopamine agonists, the apomorphine
pump which delivers apomorphine subcutaneously, and the
intraduodenal delivery of levodopa (with carbidopa)
through a percutaneous enteric gastrostomy (PEG). Both
systems have now been used for a number of years and
provide signiﬁcant beneﬁt.
Intracranial surgical attempts to control parkinsonian
symptoms are much older than these approaches. Ablative
surgery at various sites can control tremor, while newer
approaches have been developed which can also affect
other motor symptoms. The newest target is the subtha-
lamic nucleus, and rather than destructive lesions the
modern approach is to stimulate this area. Presumably the
electrical stimulation is inhibitory, although the exact
neural circuitry which is affected and the mechanism of
activity are still far from being fully understood.
Early studies in University Hospital, Grenoble, France,
have succeeded to overcome the initial reluctance of neu-
rologists to submit their patients to surgery. Over the past
two decades, several centers over the world have been able
to conﬁrm these results.
As both papers mention, there are no head-to-head
studies which compare these methods, and it is perhaps not
surprising that each center maintains the method in which it
gained experience.
The specialist facing a patient with motor ﬂuctuations
must, therefore, assume that these methods are comparable
in their outcome, and thus the decision must be made
individually in each case. The indications are similar, but
there are differences in contraindications.
As both papers stress, the ﬁnal decision as to the
choice of method must rest with the patient. However, the
critical recommendation of the specialist must depend on
the experience of the teams in the geographical area.In
that respect, DBS is signiﬁcantly more demanding. It
requires a dedicated team of neurologists, neurosurgeons,
radiologists, psychologists and neurophysiologists to
evaluate the patient and perform the surgery. Moreover,
the post-operative care may demand adjustment of the
current parameter which is usually done by the neurolo-
gist. Thus it is clear that only centers with a dedicated
team should be allowed to perform the surgical
intervention.
The Grenoble team depends on electrophysiological
identiﬁcation of the stimulation target. This time and effort
consuming procedure is not performed in several other
centers, who claim to have equally good results.
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DOI 10.1007/s00702-011-0661-2As stressed by Carron et al., the pre-surgical discussion
must clarify to the patient what are the reasonable expec-
tations. The main aim of surgery should be to prevent
motor ﬂuctuations and reduce dyskinesias. Non-motor
ﬂuctuations and freezing do not respond well. The patient
should not assume that he will be ‘‘cured’’ of PD, and be
warned that the disease will continue to develop, leading to
additional non-motor disturbances which will seriously
affect the quality of life. There is no evidence that any of
the methods discussed are neuroprotective or affect the rate
of progression.
The three approaches are very costly, and this factor
needs to be taken into consideration when selecting the
intervention.
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